Does DABRAFENIB Cause Malignant neoplasm progression? 1,667 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 1,667 reports of Malignant neoplasm progression have been filed in association with DABRAFENIB (Tafinlar). This represents 8.6% of all adverse event reports for DABRAFENIB.
1,667
Reports of Malignant neoplasm progression with DABRAFENIB
8.6%
of all DABRAFENIB reports
693
Deaths
496
Hospitalizations
How Dangerous Is Malignant neoplasm progression From DABRAFENIB?
Of the 1,667 reports, 693 (41.6%) resulted in death, 496 (29.8%) required hospitalization, and 69 (4.1%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for DABRAFENIB. However, 1,667 reports have been filed with the FAERS database.
What Other Side Effects Does DABRAFENIB Cause?
Pyrexia (3,788)
Death (2,740)
Fatigue (1,328)
Nausea (1,300)
Chills (1,235)
Rash (1,078)
Vomiting (907)
Diarrhoea (901)
Headache (697)
Asthenia (667)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which DABRAFENIB Alternatives Have Lower Malignant neoplasm progression Risk?
DABRAFENIB vs DABRAFENIB\TRAMETINIB
DABRAFENIB vs DACARBAZINE
DABRAFENIB vs DACLATASVIR
DABRAFENIB vs DACLIZUMAB
DABRAFENIB vs DACOMITINIB